Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(6)
•••
Post by HighSkies2019on Nov 02, 2021 7:34pm
134 Views
Post# 34079895

Re:RE:RE:RE:🚨 Report Greasy Garbage to IIR

Re:RE:RE:RE:🚨 Report Greasy Garbage to IIRAwe look another fan...Someone quick call 911 and put a rush on that straight jacket for Greasy Garbage a.k.a Penny ....they are loosing their sheeet spazzing all over the place ! Hey Red ...is that you trying to get me to respond .... should have just called me to the board to discuss the leaf game.... shorty shorts looks good on you ...you shorts made this stk a mess and only have yourselves to blame....now yesterday was interesting....was that the shorts trying to put a tight squeeze on the longs hoping they would scare and sell....that sharp drop down then quick rebound market manipulation at its best...I wonder if any orders had their stop loss order triggered ..or maybe was it the legal team dummping their shares since their price was at 0.20.... I am for them dumping then buying back in with the cheaper price ...taking shares out from under the noses of the shorts... new short report this week...I wonder if they added more...Hey Bud this one's for you.... I took advantage of the cheap shares ....yes call me crazy but I bought 5600 already in the green ....hey Greasy Garbage contact IIROC and let them know that I am locked and loaded...hit the GO button..... gltal
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities